Higher temperatures linked to severity of allergic conjunctivitis

Article

Temperatures measured by a newly developed non-contact ocular surface thermographer (OST) can be used to evaluate the efficacy of topical anti-allergic agents because of the significant correlation of the conjunctival surface temperature and the severity of conjunctival allergic reaction, according to recently published data.

Temperatures measured by a newly developed non-contact ocular surface thermographer (OST) can be used to evaluate the efficacy of topical anti-allergic agents because of the significant correlation of the conjunctival surface temperature and the severity of conjunctival allergic reaction, according to the results of a study published in Ophthalmic Research.

Researchers from Ehime University School of Medicine included 13 asymptomatic patients with seasonal allergic conjunctivitis due to cedar pollen. They instilled a 0.025% levocabastine ophthalmic suspension in one eye and artificial tears in the other eye, in a masked fashion 10 minutes prior to a conjunctival allergen challenge (CAC). A drop of cedar pollen solution was then given into the conjunctival sac to induce an allergic reaction.

The surface temperature of the inferior bulbar conjunctiva was measured before and 30 minutes after CAC with a newly developed non-contact ocular surface thermographer (OST) Slit-lamp biomicroscopy was also used to measure the degree of conjunctival injection and chemosis. A questionnaire was used to evaluate symptoms.

After CAC, temperatures increased by 0.67 °C in the artificial tear eyes, and only by 0.21 °C in the levocabastine eyes (P P P

To access the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.